Yantai Dongcheng Pharmaceutical Co Ltd (002675) - Total Assets
Based on the latest financial reports, Yantai Dongcheng Pharmaceutical Co Ltd (002675) holds total assets worth CN¥9.18 Billion CNY (≈ $1.34 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Yantai Dongcheng Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Yantai Dongcheng Pharmaceutical Co Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 002675 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Yantai Dongcheng Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Yantai Dongcheng Pharmaceutical Co Ltd's total assets of CN¥9.18 Billion consist of 29.0% current assets and 71.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.4% |
| Accounts Receivable | CN¥1.03 Billion | 11.1% |
| Inventory | CN¥532.57 Million | 5.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥567.83 Million | 6.1% |
| Goodwill | CN¥2.49 Billion | 26.9% |
Asset Composition Trend (2008–2025)
This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Yantai Dongcheng Pharmaceutical Co Ltd (002675) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yantai Dongcheng Pharmaceutical Co Ltd's current assets represent 29.0% of total assets in 2025, a decrease from 69.0% in 2008.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2025, up from 5.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 5.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 26.9% of total assets.
Yantai Dongcheng Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Yantai Dongcheng Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Yantai Dongcheng Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.71 | 1.60 | 1.44 |
| Quick Ratio | 1.38 | 1.21 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.08 Billion | CN¥932.18 Million | CN¥849.69 Million |
Yantai Dongcheng Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Yantai Dongcheng Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | CN¥9.26 Billion |
| Market Capitalization | $1.53 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Yantai Dongcheng Pharmaceutical Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yantai Dongcheng Pharmaceutical Co Ltd's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yantai Dongcheng Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual total assets of Yantai Dongcheng Pharmaceutical Co Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.26 Billion ≈ $1.36 Billion |
+7.27% |
| 2024-12-31 | CN¥8.63 Billion ≈ $1.26 Billion |
+6.83% |
| 2023-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
-1.16% |
| 2022-12-31 | CN¥8.18 Billion ≈ $1.20 Billion |
+6.80% |
| 2021-12-31 | CN¥7.66 Billion ≈ $1.12 Billion |
+3.56% |
| 2020-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
+1.35% |
| 2019-12-31 | CN¥7.29 Billion ≈ $1.07 Billion |
+4.70% |
| 2018-12-31 | CN¥6.97 Billion ≈ $1.02 Billion |
+32.13% |
| 2017-12-31 | CN¥5.27 Billion ≈ $771.63 Million |
+23.55% |
| 2016-12-31 | CN¥4.27 Billion ≈ $624.53 Million |
+67.51% |
| 2015-12-31 | CN¥2.55 Billion ≈ $372.84 Million |
+82.86% |
| 2014-12-31 | CN¥1.39 Billion ≈ $203.89 Million |
+13.42% |
| 2013-12-31 | CN¥1.23 Billion ≈ $179.77 Million |
+12.88% |
| 2012-12-31 | CN¥1.09 Billion ≈ $159.26 Million |
+141.19% |
| 2011-12-31 | CN¥451.24 Million ≈ $66.03 Million |
+25.62% |
| 2010-12-31 | CN¥359.19 Million ≈ $52.56 Million |
+34.55% |
| 2009-12-31 | CN¥266.96 Million ≈ $39.07 Million |
+36.84% |
| 2008-12-31 | CN¥195.09 Million ≈ $28.55 Million |
-- |
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti… Read more